# Ebola: Why Is There Still No Licensed Vaccine for Bundibugyo? Scientific challenges and logistical hurdles delay effective immunization against the recurring Ebola variant. - **Source:** [DW – Top Stories](https://www.dw.com/en) - **Published:** 2026-11-07 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/b2f87769-2695-4385-84ac-bc7642857456 ## Persistent Ebola Outbreaks Fifty years after the first documented epidemic in Zaire, the Democratic Republic of Congo faces another significant Ebola outbreak. This current crisis involves the Bundibugyo virus, a less common strain first identified in 2007. Despite decades of awareness, the lack of a licensed vaccine or official treatment remains a critical public health failure. ## Missed Research Opportunities Experts like Torsten Feldt argue that previous outbreaks in 2007 and 2012 provided ample time to develop therapeutic options. However, these opportunities were not fully utilized, leading to lost time. Researchers note that while Ebola is a predictable virus compared to HIV or influenza, vaccine development has been hindered by inconsistent funding priorities. ## The Viral Diversity Challenge Ebola is not a single virus but a genus containing distinct variants like Zaire, Sudan, and Bundibugyo. The existing licensed vaccine, Ervebo, specifically targets the Zaire strain, offering limited protection against others. Consequently, medical teams are currently unable to rely on established tools to combat the specific variant circulating in the region. ## Cross-Reactive Immune Responses A recent study by the German Center for Infection Research investigated whether Ervebo could trigger immune responses against other strains. Researchers identified cross-reactive T-cell responses against the Bundibugyo virus. While promising, the data remains insufficient to confirm if this response provides actual clinical protection or merely results in milder disease progression. ## Ethical Vaccination Dilemmas Deploying unproven vaccines during an active outbreak presents significant ethical risks. Experts warn that mass vaccination without confirmed efficacy could create a false sense of security and damage public trust. If a vaccine proves ineffective, it may lead to long-term community resistance against future, more reliable immunization efforts in affected regions. ## Logistical and Conflict Barriers Medical innovation alone cannot contain the virus in volatile environments. Conflicts, difficult transport routes, and frequent attacks on healthcare facilities severely impede containment efforts. Even with improved diagnostic tools, the physical distance between remote regions and testing labs remains a major bottleneck, delaying the rapid response necessary to stop viral transmission. ## The Tumaini Study Initiative The newly launched Tumaini study in the DRC is currently testing multiple vaccine candidates, including Ervebo and a Moderna mRNA vaccine. This research aims to generate the first reliable efficacy data against the Bundibugyo variant. However, experts estimate that widespread availability of these vaccines is unlikely before mid-2027, limiting their immediate impact. ## Future Pan-Ebola Goals The ultimate scientific objective is the development of cross-reactive pan-Ebola vaccines that provide universal protection against all known variants. While current efforts focus on the Bundibugyo strain, researchers emphasize that stopping Ebola is currently harder than identifying it. Future success depends on bridging the gap between rapid diagnosis and effective, large-scale intervention. ## Sources covering this story - https://www.dw.com/en/ebola-why-is-there-still-no-vaccine/a-79888134?maca=en-rss-en-top-1022-rdf — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._